Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Revisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughs
Frontiers in immunology, 2026;17:1899587
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Endocrine, 2026;91(1)
Co-Agonism of GLP-1R and CTR/AMYR in the Lateral Dorsal Tegmental Nucleus Produces Additive Effects on Homeostatic and Motivated Feeding
Physiology & behavior, 2026;:115478
Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study
Cureus, 2026;18(8):e114569
Semaglutide treatment fails but might prevent Alzheimer’s disease
Lancet (London, England);408(10555):602-603
Liver Organoids: From Disease Modelling to Regenerative Medicine
Cell proliferation, 2026;:e70268
Gastric content and aspiration risk after semaglutide cessation: a reply
Anaesthesia, 2026
Evaluation of tirzepatide as an adjunct to buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale
Contemporary clinical trials, 2026;:108437
Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study
Journal of diabetes and its complications, 2026;:109391
GLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey
Obesity pillars, 2026;19:100316
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Nutrients, 2026;18(16)
GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease
Frontiers in neuroscience, 2026;20:1906426
Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction
Frontiers in nutrition, 2026;13:1914155
Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes
Frontiers in endocrinology, 2026;17:1895420
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
The lancet. Diabetes & endocrinology, 2026
Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials
PloS one, 2026;21(8):e0345032
Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes
PloS one, 2026;21(8):e0354497
Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter
Canadian journal of kidney health and disease, 2026;13:20543581261476643
Serum GDF3 is Associated with Visceral Obesity, Insulin Resistance, and Inflammation in Non-Diabetic Adults: A Cross-Sectional Study with an Interventional Component
Diabetes, metabolic syndrome and obesity : targets and therapy, 2026;19:609998
Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study
Diabetes, metabolic syndrome and obesity : targets and therapy, 2026;19:607678